|Description||MK-8718 has been found to be a HIV protease inhibitor and could be studied in HIV research.|
|Synonyms||MK-8718; MK 8718; MK8718; ((3S,6R)-6-(2-(3-((2S,3S)-2-amino-3-(4-chlorophenyl)-3-(3,5-difluorophenyl)propanamido)-5-fluoropyridin-4-yl)ethyl)morpholin-3-yl)methyl (2,2,2-trifluoroethyl)carbamate|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
BMS-187071 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb.
A potent inhibitor of HIV-l protease (IC50= 1 nM)
BMS-186318 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb.
CC-3052, a thalidomide analogue, reduces persistent activation of the TNF-α system in HIV without markedly impairing neutrophil viability.
CGP-75355 is an HIV Protease inhibitor (EC50= 0.7 nM).
CI-1029 is a nonpeptidic inhibitor of HIV protease, potenat against mutant HIV protease and resistant HIV strains.
DPC-681, sulfonamide derivatives, is an extremely potent and selective inhibitor of HIV protease. IC90s: wild-type HIV-1=4-40 nM
MK-8718 has been found to be a HIV protease inhibitor and could be studied in HIV research.